GTX (GTXI) Downgraded to “Hold” at BidaskClub
GTX (NASDAQ:GTXI) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, September 20th.
Separately, Zacks Investment Research upgraded GTX from a “sell” rating to a “hold” rating in a report on Tuesday, July 17th. Five equities research analysts have rated the stock with a hold rating, The company has an average rating of “Hold” and an average target price of $31.00.
Shares of NASDAQ:GTXI traded up $0.22 during trading on Thursday, reaching $1.72. The stock had a trading volume of 2,212,891 shares, compared to its average volume of 704,781. GTX has a 1-year low of $1.32 and a 1-year high of $25.60. The firm has a market capitalization of $37.75 million, a PE ratio of -0.98 and a beta of 1.67.
In related news, VP Diane C. Young sold 2,049 shares of the business’s stock in a transaction on Monday, July 16th. The stock was sold at an average price of $14.70, for a total transaction of $30,120.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 40.90% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in GTXI. Rock Springs Capital Management LP acquired a new position in GTX during the 1st quarter worth $6,284,000. BlackRock Inc. boosted its position in shares of GTX by 129.5% during the 2nd quarter. BlackRock Inc. now owns 390,150 shares of the biopharmaceutical company’s stock worth $5,973,000 after acquiring an additional 220,114 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of GTX during the 1st quarter worth about $1,917,000. Federated Investors Inc. PA acquired a new position in shares of GTX during the 1st quarter worth about $1,558,000. Finally, Millennium Management LLC boosted its position in shares of GTX by 107.0% during the 1st quarter. Millennium Management LLC now owns 121,957 shares of the biopharmaceutical company’s stock worth $2,165,000 after acquiring an additional 63,051 shares in the last quarter. 28.38% of the stock is owned by hedge funds and other institutional investors.
GTX Company Profile
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.
Further Reading: How can investors find ex-dividend dates?
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.